Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States.

Many eculizumab recipients had an undetermined indication for eculizumab use; few were up-to-date for recommended meningococcal vaccines or were prescribed antibiotics long-term. These findings can inform further investigation of how to best protect this population from meningococcal disease.